Keyword: ASCO

At last year’s ASCO, AstraZeneca posted Lynparza data that would win the class' first breast cancer nod. Now it’s aiming for prostate cancer.

Merck spent on-stage ASCO time with new Keytruda data, but behind the scenes, it huddled with teams from its big new partners, AstraZeneca and Eisai.

Merck’s Keytruda has a solo OK for first-line lung cancer patients whose tumors bear high levels of PD-L1. But that group will likely soon get bigger.

At this year's ASCO, squamous lung cancer has elbowed nonsquamous disease off center stage—but once again, it's Merck & Co. stealing the spotlight.

Despite some trial setbacks, Bristol-Myers' Opdivo still leads the I-O pack by U.S. revenue. But wins for rival Keytruda could change that soon.

Nanjing Legend Biotech reported 100% ORR for a CAR-T product, Chi-Med touted fruquintinib's low liver toxicity, Eisai's Lenvima could challenge Bayer's Nexavar and more.

Today, we’re bringing you the choicest quotes we collected from interviews over ASCO weekend.

If Bristol-Myers Squibb needed more evidence to suggest it had lost the immuno-oncology lead to Merck & Co., it got it at ASCO.

Let’s just say investors were hoping for more from the Perjeta-Herceptin combo data Roche unveiled at ASCO.

Last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—doesn’t look so impressive anymore, thanks to data rolled out at ASCO.